Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Ultragenyx Pharmaceutical Inc.
< Previous
1
2
3
Next >
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 20, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
November 09, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
November 05, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update
October 29, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 18, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
October 07, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
October 03, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
September 26, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 18, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx to Participate in Investor Conferences in September
August 29, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 21, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
August 01, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
July 25, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
July 24, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 19, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
July 17, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 20, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
June 13, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 12, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
June 12, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
June 11, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
MREO
RARE
Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
May 30, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
May 07, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
May 02, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
April 30, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
April 30, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
April 25, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 19, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.